Lenalidomide as potential treatment in small cell neuroendocrine lung cancer with del 5q
Journal: Scientific Journal of Genetics and Gene Therapy (Vol.4, No. 1)Publication Date: 2018-07-28
Abstract
Lung cancer is a leading cause of cancer deaths world-wide, with the carcinogens in tobacco smoke playing a major etiologic role. Genetic changes responsible for carcinogenesis include activation of proto-oncogenes and inactivation of tumor suppressor genes. Tumor suppressor gene inactivation is contributed to, in part, by loss of chromosomal DNA. While cytogenetic findings in small cell neuroendocrine lung carcinoma are complex, 5q deletion is among the most frequently identified [1,2].
Other Latest Articles
- Strategies for investigating the genetics of chronic kidney disease
- Caveolin-1 in renal disease
- Triplet with Dicephalus Twins: A Case Report
- African Medicinal Plants that Can Control or Cure Tuberculosis
- Spray dried self-nanoemulsifying drug delivery systems for sertraline HCl: Pharmacokinetic study in healthy volunteers
Last modified: 2019-01-10 21:10:49